Telix Pharmaceuticals (TLX) Competitors

$10.34 -0.49 (-4.49%)

As of 02:49 PM Eastern

TLX vs. RGC, ASND, BBIO, SMMT, and AXSM

Should you buy Telix Pharmaceuticals stock or one of its competitors? MarketBeat compares Telix Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Telix Pharmaceuticals include Regencell Bioscience (RGC), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Summit Therapeutics (SMMT), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

How does Telix Pharmaceuticals compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Telix Pharmaceuticals (NASDAQ:TLX) are both pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

0.1% of Regencell Bioscience shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Regencell Bioscience has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Telix Pharmaceuticals	N/A	N/A	N/A

Regencell Bioscience has higher earnings, but lower revenue than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Telix Pharmaceuticals	$803.79M	4.36	-$7.12M	N/A	N/A

In the previous week, Regencell Bioscience had 23 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 33 mentions for Regencell Bioscience and 10 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 1.41 beat Regencell Bioscience's score of -0.01 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	2 Positive mention(s)	25 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Telix Pharmaceuticals	3 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals has a consensus target price of $21.13, indicating a potential upside of 104.22%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Telix Pharmaceuticals is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

Telix Pharmaceuticals beats Regencell Bioscience on 6 of the 10 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

Ascendis Pharma A/S currently has a consensus target price of $291.50, indicating a potential upside of 20.64%. Telix Pharmaceuticals has a consensus target price of $21.13, indicating a potential upside of 104.22%. Given Telix Pharmaceuticals' higher possible upside, analysts plainly believe Telix Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Ascendis Pharma A/S has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market.

Ascendis Pharma A/S has a net margin of 57.87% compared to Telix Pharmaceuticals' net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Telix Pharmaceuticals	N/A	N/A	N/A

Telix Pharmaceuticals has lower revenue, but higher earnings than Ascendis Pharma A/S.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	18.50	-$258M	$8.67	27.87
Telix Pharmaceuticals	$803.79M	4.36	-$7.12M	N/A	N/A

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 12 mentions for Ascendis Pharma A/S and 10 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 1.41 beat Ascendis Pharma A/S's score of 1.23 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	3 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascendis Pharma A/S beats Telix Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to BridgeBio Pharma?

Telix Pharmaceuticals (NASDAQ:TLX) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Telix Pharmaceuticals currently has a consensus target price of $21.13, indicating a potential upside of 104.22%. BridgeBio Pharma has a consensus target price of $88.19, indicating a potential upside of 35.19%. Given Telix Pharmaceuticals' higher probable upside, equities analysts plainly believe Telix Pharmaceuticals is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
BridgeBio Pharma	1 Sell rating(s)	0 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.92

Telix Pharmaceuticals has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market.

99.9% of BridgeBio Pharma shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Telix Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
BridgeBio Pharma	-124.42%	N/A	-65.81%

Telix Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.36	-$7.12M	N/A	N/A
BridgeBio Pharma	$502.08M	25.45	-$724.93M	-$3.74	N/A

In the previous week, BridgeBio Pharma had 25 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 35 mentions for BridgeBio Pharma and 10 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 1.41 beat BridgeBio Pharma's score of 0.35 indicating that Telix Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	3 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	10 Very Positive mention(s)	0 Positive mention(s)	16 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Telix Pharmaceuticals and BridgeBio Pharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Summit Therapeutics?

Telix Pharmaceuticals (NASDAQ:TLX) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

4.6% of Summit Therapeutics shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Summit Therapeutics had 5 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 15 mentions for Summit Therapeutics and 10 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 1.41 beat Summit Therapeutics' score of 1.09 indicating that Telix Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	3 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.25, suggesting that its share price is 225% less volatile than the broader market.

Telix Pharmaceuticals currently has a consensus target price of $21.13, indicating a potential upside of 104.22%. Summit Therapeutics has a consensus target price of $27.58, indicating a potential upside of 45.48%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Telix Pharmaceuticals is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Summit Therapeutics	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.50

Telix Pharmaceuticals has higher revenue and earnings than Summit Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.36	-$7.12M	N/A	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

Telix Pharmaceuticals' return on equity of 0.00% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Summit Therapeutics	N/A	-291.24%	-243.07%

Summary

Telix Pharmaceuticals beats Summit Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Axsome Therapeutics?

Telix Pharmaceuticals (NASDAQ:TLX) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

81.5% of Axsome Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Axsome Therapeutics had 16 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 26 mentions for Axsome Therapeutics and 10 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 1.41 beat Axsome Therapeutics' score of 0.32 indicating that Telix Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	3 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Telix Pharmaceuticals has a beta of 0.08, suggesting that its stock price is 92% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market.

Telix Pharmaceuticals currently has a consensus price target of $21.13, indicating a potential upside of 104.22%. Axsome Therapeutics has a consensus price target of $251.26, indicating a potential upside of 12.47%. Given Telix Pharmaceuticals' higher possible upside, equities research analysts plainly believe Telix Pharmaceuticals is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

Telix Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.36	-$7.12M	N/A	N/A
Axsome Therapeutics	$638.50M	18.00	-$183.17M	-$3.73	N/A

Telix Pharmaceuticals has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Telix Pharmaceuticals' return on equity of 0.00% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Summary

Telix Pharmaceuticals and Axsome Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Telix Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLX vs. The Competition

Export

Metric	Telix Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.51B	$3.41B	$6.28B	$12.10B
Dividend Yield	N/A	2.25%	2.78%	5.23%
P/E Ratio	N/A	15.30	20.55	25.41
Price / Sales	4.36	303.37	545.88	75.53
Price / Cash	253.30	56.93	27.81	36.29
Price / Book	8.41	6.85	9.62	6.65
Net Income	-$7.12M	$24.11M	$3.55B	$333.40M
7 Day Performance	-6.30%	-1.57%	-0.36%	-0.58%
1 Month Performance	-1.86%	3.83%	5.99%	7.66%
1 Year Performance	-36.34%	71.34%	38.59%	35.36%

Telix Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLX Telix Pharmaceuticals	4.6862 of 5 stars	$10.34 -4.5%	$21.13 +104.2%	-37.0%	$3.51B	$803.79M	N/A	1,184	Positive News
RGC Regencell Bioscience	0.2881 of 5 stars	$27.36 -6.0%	N/A	N/A	$14.40B	N/A	N/A	10	Earnings Report Gap Up
ASND Ascendis Pharma A/S	4.5227 of 5 stars	$228.71 +3.5%	$291.56 +27.5%	+57.8%	$13.78B	$720.13M	N/A	1,189	Positive News Earnings Report Analyst Upgrade
BBIO BridgeBio Pharma	3.4386 of 5 stars	$68.99 +0.6%	$87.71 +27.1%	+89.3%	$13.42B	$502.08M	N/A	400	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision
SMMT Summit Therapeutics	3.1011 of 5 stars	$16.98 +5.4%	$27.58 +62.4%	-22.1%	$12.51B	N/A	N/A	110	Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLX) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Telix Pharmaceuticals (TLX) Competitors

TLX vs. RGC, ASND, BBIO, SMMT, and AXSM

How does Telix Pharmaceuticals compare to Regencell Bioscience?

Summary

How does Telix Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does Telix Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does Telix Pharmaceuticals compare to Summit Therapeutics?

Summary

How does Telix Pharmaceuticals compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLX vs. The Competition

Telix Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Telix Pharmaceuticals (TLX) Competitors

TLX vs. RGC, ASND, BBIO, SMMT, and AXSM

How does Telix Pharmaceuticals compare to Regencell Bioscience?

Do institutionals & insiders believe in RGC or TLX?

Which has more volatility & risk, RGC or TLX?

Is RGC or TLX more profitable?

Which has higher valuation & earnings, RGC or TLX?

Does the media prefer RGC or TLX?

Do analysts prefer RGC or TLX?

Summary

How does Telix Pharmaceuticals compare to Ascendis Pharma A/S?

Do analysts prefer ASND or TLX?

Which has more risk and volatility, ASND or TLX?

Is ASND or TLX more profitable?

Which has better valuation and earnings, ASND or TLX?

Does the media refer more to ASND or TLX?

Summary

How does Telix Pharmaceuticals compare to BridgeBio Pharma?

Do analysts rate TLX or BBIO?

Which has more risk and volatility, TLX or BBIO?

Do insiders and institutionals have more ownership in TLX or BBIO?

Is TLX or BBIO more profitable?

Which has preferable valuation & earnings, TLX or BBIO?

Does the media prefer TLX or BBIO?

Summary

How does Telix Pharmaceuticals compare to Summit Therapeutics?

Do insiders and institutionals have more ownership in TLX or SMMT?

Does the media prefer TLX or SMMT?

Which has more risk and volatility, TLX or SMMT?

Do analysts rate TLX or SMMT?

Which has preferable valuation & earnings, TLX or SMMT?

Is TLX or SMMT more profitable?

Summary

How does Telix Pharmaceuticals compare to Axsome Therapeutics?

Do institutionals and insiders have more ownership in TLX or AXSM?

Does the media favor TLX or AXSM?

Which has more volatility & risk, TLX or AXSM?

Do analysts rate TLX or AXSM?

Which has better earnings & valuation, TLX or AXSM?

Is TLX or AXSM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLX vs. The Competition

Telix Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools